INTRODUCTION {#s1}
============

Great quantities of previous articles have reported that expression levels of microRNAs (miRNAs) are associated with survival time of gastric cancer (GC) patients \[[@R1]--[@R167]\]. GC is still the fourth most common cancer all over the world and the second most universal cause of cancer death globally, although there has been a constant descent in morbidity and mortality in the past few decades \[[@R168], [@R169]\]. The early clinical inspection of GC was under 15%, and cases of advanced GC accounted for 85% \[[@R170]\]. At present, the primary treatment choices are surgical intervention, chemotherapy, immunogene therapy, and target therapy. The clinical result of GC mainly depends on the stage of tumor. Unfortunately, GC patients' median survival time is no more than 6-9 months \[[@R171]\]. It is unlimited proliferation of cancer cells and ability of intense invasive and metastasis that mainly causes high malignancy degree and poorer survival time. As a result, a novel diagnostic means and improved prognosis of GC might be created through identification of molecular aberrations, which can predict cancer progression and survival rate.

During the past decade, the associations between non-coding RNAs (ncRNAs) and GC have been widely researched. Generally speaking, ncRNAs have been classified as small ncRNAs, consisting of miRNAs and long non-coding RNAs (lncRNAs).

MiRNAs, a novel class of small (20-24 nucleotides \[nt\]) non-coding regulatory RNAs, play a significant role in multiple biological processes, such as cell division, differentiation, senescence and apoptosis \[[@R172], [@R173]\]. An increasing number of evidence shows that various miRNAs are unconventionally expressed in diverse types of human cancers, and a few miRNAs have been shown to be related with tumor formation, development, progression, and response to treatment by miRNA expression profiling \[[@R174]\].

Moreover, a series of studies have already demonstrated that lncRNAs also play crucial roles in GC progression. A previous investigation reported that, compared with non-tumor tissues, H19 was one of the most elevated lncRNAs with a ˜8.91-fold change in human primary GC \[[@R175]\]. In addition, Li et al. \[[@R176]\] recognized certain potential lncRNAs that abnormally expressed between GC and normal tissues by screening a cohort of 74 GC patients as well, among which, H19 was chosen as a result of a significant overexpression. Furthermore, expression levels of the lncRNAs H19, ANRIL, GHET1, HOTAIR, GAS5, LET, GAPLINC and FENDRR are also significantly associated with the 5-year survival rate of GC patients \[[@R176]--[@R183]\].

In GC research area, quite a number of investigations have demonstrated that miRNAs are associated with survival time of patients \[[@R1]--[@R167]\]. However, the number of patients during the articles mentioned above is generally not big enough. Therefore, a systematic review and meta-analysis was performed for the sake of better understanding accurate prognostic value between expression levels of numerous miRNAs and HR of GC patients.

RESULTS {#s2}
=======

Study selection {#s2_1}
---------------

A flow diagram with details of the study selection process was presented in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of literature search and selection](oncotarget-08-55489-g001){#F1}

Study frequency {#s2_2}
---------------

Frequency of studies estimating prognostic value of miRNAs in GC were shown in Table [1](#T1){ref-type="table"} (highlighted studies were included in the present meta-analysis), including miRNA name, number of studies estimating prognostic value, and reference.

###### Frequency of studies estimating prognostic value of miRNAs in gastric cancer

  miRNA    N   R           miRNA     N   R         miRNA     N   R         miRNA     N   R          miRNA   N   R              miRNA    N   R            miRNA     N   R
  -------- --- ----------- --------- --- --------- --------- --- --------- --------- --- ---------- ------- --- -------------- -------- --- ------------ --------- --- ------------
  let-7g   1   1           27b       3   32-34     126       2   54,55     148a      1   78         200a    1   3              328      1   126          485-5p    1   146
  10b      1   2           29a       2   35,36     128       2   32,34     150-5p    1   77         200b    2   96,97          335      3   41,127,128   486-5p    3   56,147,148
  15a      1   3           29b       1   36        129-5p    1   56        150       2   12,79      200c    4   66,96,98,99    337-3p   1   129          493       1   149
  16       2   3,4         29c       1   36        130a      1   57        153       1   80         203     2   100,101        340      1   130          494       1   150
  17-5p    2   5,6         29        1   19        132       1   58        181a-5p   1   81         204     2   102,103        342-3p   1   79           500       1   151
  18a      2   7,8         31        1   37        133a-3p   1   56        181b      1   16         206     3   104-106        361-5p   1   131          501-5p    1   152
  19a      1   9           34a       5   3,38-41   133       2   59,60     181c      1   82         210     1   107            363      1   132          503       1   153
  19b      1   10          92a       2   11,42     135a      1   61        182-5p    1   56         211     1   108            375      1   68           506       3   154-156
  20a      3   3,5,11      93        2   43,44     135b-5p   1   56        183-5p    1   56         212     1   109            377      1   133          508-5p    2   33,157
  20b      3   3,12,13     100       1   34        135b      1   61        183       2   83,84      214     4   1,34,110,111   378      1   134          520c      1   158
  21-5p    1   14          101       2   32,34     137       3   62-64     185       2   3,85       215     1   87             381      1   135          520d-3p   1   159
  21       7   3,6,15-19   103       1   3         141       3   65-67     187       1   86         217     2   112,113        421      2   136,137      558       1   160
  22       2   20,21       106a      2   3,6       142-5p    1   68        192       3   48,79,87   218     3   114-116        425      1   3            590-5p    1   161
  23b-3p   1   22          106b      3   3,6,45    143       3   3,69,70   193b      1   88         221     2   117,118        429      1   138          630       1   162
  23b      1   23          107       3   3,46,47   144-5p    1   56        194       1   89         222     2   118,119        433      1   1            873       1   163
  24       1   24          122       1   48        144       1   71        196a      4   88,90-92   223     2   120,121        448      1   139          939       1   164
  25       2   25,26       125a-3p   1   49        145-5p    2   56,72     196b-5p   1   56         224     2   79,122         449c     1   140          940       1   165
  26a      2   27,28       125a-5p   1   50        145       2   34,73     196b      3   91-93      300     1   123            451      4   4,141-143    1207-5p   1   166
  26b      1   29          125a      1   51        146a      3   74-76     198       1   94         301a    1   124            452      1   144          1225-5p   1   167
  27a      2   30,31       125b      2   52,53     146b-5p   1   77        199a      1   95         326     1   125            455-5p   1   145          1266      1   166

Highlighted studies were included in the present meta-analysis; N: Number of studies estimating prognostic value; R: Reference.

Study characteristics {#s2_3}
---------------------

Characteristics of articles with Kaplan-Meier survival curves in GC were comprehensively detailed in Table [2](#T2){ref-type="table"}, including miRNA name, names of the first authors, publication year, reference number, country, study design, detected sample, number of patients, stage, cut-off value, main miRNA method, maximum months of follow-up, survival analysis and HR of low or high expression on the basis of relevant survival analysis with 95%CI. If the data were not provided visually and only as Kaplan-Meier survival curves, the data were extracted from the graphical survival plots, and estimations of the HR with 95%CI were then performed using a previously described method \[[@R184]\] with the software Engauge Digitizer version 4.1. Furthermore, if both the univariate and multivariate results were reported, then only the latter was selected, since these results were adjusted for confounding factors.

###### Characteristics of articles with Kaplan-Meier survival curves in gastric cancer

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  miRNA     Study                                   Country                   Study design   Sample   Number   Stage    Cut-off    Method       Follow-up (month)   Result   HR(L/H)    HR(H/L)    95%CI
  --------- --------------------------------------- ------------------------- -------------- -------- -------- -------- ---------- ------------ ------------------- -------- ---------- ---------- ---------------------
  20a       Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     37       II-III   70%        qRT-PCR      60                  OS^u^               1.93       0.48-7.87

  20a       Wang M, 2012 \[[@R5]\]                  China                     R              Plasma   65       I-IV     0.26       RT-qPCR      36                  OS^m^               1.58       1.10-2.25

  20a       Wu Q, 2013 \[[@R11]\]                   China                     R              FFPE     97       None     Median     qRT-PCR      66                  OS^m^               1.01       1.00-1.02

  20b       Katada T, 2009 \[[@R12]\]               Japan                     R              Frozen   42       None     None       qRT-PCR      60                  OS^m^               2.01       0.59-6.85

  20b       Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     34       II-III   70%        qRT-PCR      60                  OS^u^               1.21       0.20-7.23

  20b       Xue TM, 2015 \[[@R13]\]                 China                     R              Tissue   102      I-IV     Median     RT-qPCR      75                  OS^m^               3.32       1.20-9.14

  21-5p     Park SK, 2016 \[[@R14]\]                Korea                     R              FFPE     50       III      ROC        qRT-PCR      168                 RFS^u^              2.05       1.26-3.34

  21        Jiang J, 2011 \[[@R15]\]                China                     R              FFPE     55       III-IV   None       qRT-PCR      17                  OS^u^               5.88       2.22-16.67

  21        Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     33       II-III   70%        qRT-PCR      60                  OS^u^               2.58       0.34-19.79

  21        Xu Y, 2012 \[[@R16]\]                   China                     R              Frozen   86       I-IV     5.12       qRT-PCR      36                  OS^u^               1.15       0.59-2.25

  21        Hirata K, 2013 \[[@R17]\]               Japan                     P              Tissue   61       None     3.58       IHC          42                  RFS^u^              0.82       0.27-2.43

  21        Komatsu S, 2013 \[[@R6]\]               Japan                     R              Plasma   69       I-IV     0.03       qRT-PCR      40                  CSS^m^              13.39      1.72-104.42

  21        Song J, 2013 \[[@R18]\]                 China                     R              Serum    103      I-IV     0.64       qRT-PCR      54                  OS^u^               0.99       0.48-2.07

  21        Wang D, 2015 \[[@R19]\]                 China                     R              Tissue   50       I-IV     ROC        qRT-PCR      12                  OS^u^               1.89       1.17-3.07

  27b       Liu HT, 2015 \[[@R32]\]                 China                     R              FFPE     103      I-IV     None       qRT-PCR      66                  OS^u^    0.80                  0.46-1.41

  27b       Shang Y, 2016 \[[@R33]\]                China                     R              Tissue   114      I-IV     None       ISH          84                  OS^u^    1.61                  0.92-2.80

  27b       Liu HT, 2017 \[[@R34]\]                 China                     R              FFPE     102      I-IV     Median     RT-qPCR      67                  OS^m^    1.33                  0.60-2.98

  34a       Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     37       II-III   70%        qRT-PCR      60                  OS^u^    0.20                  0.06-0.68

  34a       Hui WT, 2015 \[[@R38]\]                 China                     R              Frozen   76       I-III    Mean       qRT-PCR      \>60                OS^m^    2.33                  1.10-4.93

  34a       Wei B, 2015 \[[@R39]\]                  TCGA                      R              Tissue   157      I-IV     X-tile     Downloaded   \>100               OS^u^    2.31                  0.13-40.12

  34a       Zhang H, 2015 \[[@R40]\]                China                     R              Frozen   137      I-IV     2.44       qRT-PCR      68                  OS^m^    1.33                  1.14-1.61

  34a       Yang B, 2016 \[[@R41]\]                 China                     R              Tissue   50       I-IV     Median     qRT-PCR      60                  OS^u^    3.05                  0.60-15.50

  106b      Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     37       II-III   70%        qRT-PCR      60                  OS^u^               2.70       0.43-17.06

  106b      Komatsu S, 2013 \[[@R6]\]               Japan                     R              Plasma   69       I-IV     0.05       qRT-PCR      40                  CSS^u^              1.22       0.52-2.84

  106b      Yang TS, 2014 \[[@R45]\]                China                     R              Tissue   120      None     Median     qRT-PCR      45                  OS^u^               1.79       1.10-2.90

  107       Li X, 2011 \[[@R46]\]                   China                     R              FFPE     50       None     90.95      qRT-PCR      48                  OS^u^               0.48       0.28-0.82

  107       Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     37       II-III   70%        qRT-PCR      60                  OS^u^               4.09       1.26-13.32

  107       Inoue T, 2012 \[[@R47]\]                Japan                     R              Frozen   161      I-IV     2.74       RT-qPCR      60                  OS^m^               2.21       1.18-4.61

  125a-3p   Hashiguchi Y, 2012 \[[@R49]\]           Japan                     R              Frozen   70       I-IV     7.42       RT-qPCR      147.6               OS^u^    3.01                  1.26-7.20

  125a-5p   Nishida N, 2011 \[[@R50]\]              Japan                     R              Frozen   87       I-IV     None       RT-qPCR      147.6               OS^u^    2.16                  0.96-4.86

  125a      Dai J, 2015 \[[@R51]\]                  China                     R              FFPE     73       I-IV     None       qRT-PCR      62                  OS^u^    1.31                  0.54-3.18

  137       Gu Q, 2015 \[[@R62]\]                   China Set IChina Set II   R              Frozen   6787     I-III    Median     qRT-PCR      96                  OS^m^\   6.802.41              2.06-22.481.13-5.11
                                                                                                                                                                    OS^m^                          

  137       Zheng X, 2015 \[[@R63]\]                China                     R              FFPE     38       I-IV     Median     qRT-PCR      56                  DFS^u^   2.70                  1.18-6.17

  137       Du Y, 2016 \[[@R64]\]                   China                     R              Tissue   14       I-IV     0.01       qRT-PCR      96                  OS^u^    2.49                  0.32-19.59

  141       Lu YB, 2015 \[[@R65]\]                  China                     R              Frozen   95       I-IV     Median     qRT-PCR      60                  OS^m^    2.97                  1.30-10.00

  141       Zhou X, 2015 \[[@R66]\]                 China                     R              Frozen   63       IIB-IV   Median     qRT-PCR      \>30                DFS^u^   2.47                  1.22-5.00

  141       Huang M, 2016 \[[@R67]\]                China                     R              Frozen   30       I-IV     None       qRT-PCR      26.83               OS^u^    2.23                  1.04-4.79

  143       Osawa S, 2011 \[[@R3]\]                 Japan                     R              FFPE     37       II-III   70%        qRT-PCR      60                  OS^u^               2.95       0.19-46.23

  143       Naito Y, 2014 \[[@R69]\]                Japan                     R              Frozen   66       I-IV     1/3        qRT-PCR      50                  CSS^m^              2.62       1.21-5.80

  143       Li JH, 2016 \[[@R70]\]                  China                     R              Frozen   44       I-IV     1.18       qRT-PCR      26                  OS^u^               0.40       0.23-0.70

  145-5p    Zhang Y, 2016 \[[@R72]\]                China                     R              Frozen   145      I-IV     None       RT-qPCR      66                  OS^m^    3.87                  1.13-11.44

  145-5p    Li CY, 2017 \[[@R56]\]                  TCGA                      R              Tissue   361      I-IV     None       Downloaded   60                  OS^u^    1.37                  1.08-1.74

  145       Naito Y, 2014 \[[@R73]\]                Japan                     R              FFPE     71       I-IV     Median     qRT-PCR      66.67               CSS^m^   0.71                  0.33-1.49

  145       Liu HT, 2017 \[[@R34]\]                 China                     R              FFPE     102      I-IV     Median     RT-qPCR      67                  OS^u^    1.68                  0.87-3.25

  146a      Kogo R, 2011 \[[@R74]\]                 Japan                     R              Frozen   90       I-IV     Median     qRT-PCR      132                 OS^u^    2.20                  1.31-3.70

  146a      Hou Z, 2012 \[[@R75]\]                  China                     R              FFPE     30       I-IV     0.34       qRT-PCR      36                  OS^u^    2.59                  1.24-5.39

  146a      Luo Z, 2017 \[[@R76]\]                  China                     R              Frozen   93       III-IV   ROC        RT-qPCR      72                  OS^u^    7.75                  1.66-35.71

  150-5p    Yoon SO, 2016 \[[@R77]\]                Korea                     R              FFPE     140118   I-IV     2.00       RT-qPCR      101.8               OS^m^\              0.881.84   0.37-2.090.98-3.43
                                                                                                                                                                    RFS^u^                         

  150       Katada T, 2009 \[[@R12]\]               Japan                     R              Frozen   42       None     None       qRT-PCR      60                  OS^m^               6.10       0.76-50.00

  150       Smid D, 2016 \[[@R79]\]                 Czech                     R              FFPE     4140     None     6.006.70   qRT-PCR      \>100               OS^u^\              1.912.08   1.14-3.211.11-3.91
                                                                                                                                                                    PFS^u^                         

  183-5p    Li CY, 2017 \[[@R56]\]                  TCGA                      R              Tissue   361      I-IV     None       Downloaded   60                  OS^u^    0.64                  0.47-0.87

  183       Cao LL, 2014 \[[@R83]\]                 China                     R              Frozen   52       I-IV     3.55       qRT-PCR      60                  OS^u^    2.83                  1.31-6.10

  183       Xu L, 2014 \[[@R84]\]                   China                     R              Tissue   65       I-IV     Median     RT-qPCR      102                 OS^u^    1.94                  1.11-3.39

  192       Chen Q, 2014 \[[@R48]\]                 China                     R              Plasma   61       III-IV   2.00       qRT-PCR      43                  OS^m^               0.89       0.39-2.04

  192       Xu YJ, 2015 \[[@R87]\]                  China                     R              Frozen   38       I-IV     None       qRT-PCR      81                  OS^u^               0.99       0.96-1.02

  192       Smid D, 2016 \[[@R79]\]                 Czech                     R              FFPE     41       None     2.30       qRT-PCR      \>100               OS^u^               7.43       2.71-20.41

  196a      Sun M, 2012 \[[@R90]\]                  China                     R              Frozen   31       II-IV    40.90      RT-qPCR      36                  OS^u^               4.19       1.78-9.83

  196a      Mu YP, 2014 \[[@R88]\]                  China                     R              Frozen   48       I-IV     5.69       qRT-PCR      60                  OS^u^               2.88       1.43-5.79

  196a      Tsai MM, 2014 \[[@R91]\]                China                     R              Tissue   109      I-IV     77.30      qRT-PCR      60                  OS^u^               2.27       1.50-3.43

  196a      Tsai MM, 2016 \[[@R92]\]                China                     R              Plasma   98       I-IV     1.15       qRT-PCR      72                  OS^m^               3.06       1.10-8.50

  196b-5p   Li CY, 2017 \[[@R56]\]                  TCGA                      R              Tissue   361      I-IV     None       Downloaded   60                  OS^u^               2.07       1.37-3.13

  196b      Lim JY, 2013 \[[@R93]\]                 South Korea               R              Frozen   57       I-IV     None       qRT-PCR      75                  OS^u^               1.50       1.06-2.12

  196b      Tsai MM, 2014 \[[@R91]\]                China                     R              Tissue   109      I-IV     21.70      qRT-PCR      60                  OS^u^               1.55       1.16-2.06

  196b      Tsai MM, 2016 \[[@R92]\]                China                     R              Plasma   98       I-IV     0.93       qRT-PCR      72                  OS^m^               2.91       1.04-8.17

  200c      Valladares-Ayerbes M, 2012 \[[@R98]\]   Spain                     R              Blood    52       I-IV     62.4       qRT-PCR      54                  OS^m^\   0.450.44              0.22-0.920.21-0.92
                                                                                                                                                                    PFS^m^                         

  200c      Tang H, 2013 \[[@R96]\]                 China                     R              Tissue   126      I-IV     2.00       qRT-PCR      58                  OS^u^\   2.291.83              1.38-3.811.15-2.92
                                                                                                                                                                    DFS^u^                         

  200c      Zhang HP, 2015 \[[@R99]\]               China                     R              Serum    98       I-IV     Median     qRT-PCR      60                  OS^m^    0.25                  0.10-0.37

  200c      Zhou X, 2015 \[[@R66]\]                 China                     R              Frozen   63       IIB-IV   Median     qRT-PCR      \>30                DFS^u^   1.70                  1.21-2.38

  206       Yang Q, 2013 \[[@R104]\]                China                     R              Tissue   98       I-IV     2.40       RT-qPCR      139                 OS^m^    2.56                  1.13-5.82

  206       Shi H, 2015 \[[@R105]\]                 China                     R              Frozen   220      I-IV     Median     qRT-PCR      60                  OS^m^    6.82                  1.51-21.29

  206       Hou CG, 2016 \[[@R106]\]                China                     R              Serum    150      I-III    Median     RT-qPCR      60                  OS^m^    2.39                  1.16-4.91

  214       Ueda T, 2010 \[[@R1]\]                  Japan                     R              Frozen   101      I-IV     None       qRT-PCR      102.33              OS^m^               2.70       1.30-5.61

  214       Yang TS, 2013 \[[@R110]\]               China                     R              Frozen   120      I-IV     None       qRT-PCR      45                  OS^u^               1.77       1.06-2.96

  214       Wang YW, 2014 \[[@R111]\]               China                     R              FFPE     80       I-IV     Median     RT-qPCR      72                  OS^u^               1.20       0.67-2.15

  214       Liu HT, 2017 \[[@R34]\]                 China                     R              FFPE     102      I-IV     Median     RT-qPCR      67                  OS^m^               2.75       1.12-6.76

  218       Tie J, 2010 \[[@R114]\]                 China                     R              Frozen   40       I-IV     13.81      qRT-PCR      72                  OS^u^    2.33                  1.40-3.89

  218       Xin SY, 2014 \[[@R115]\]                China                     R              Serum    68       I-IV     None       qRT-PCR      36                  OS^m^    3.16                  1.06-9.40

  218       Wang XX, 2016 \[[@R116]\]               China                     R              Tissue   112      I-IV     Median     qRT-PCR      60                  OS^m^    3.19                  1.55-8.37

  335       Yan Z, 2012 \[[@R127]\]                 China                     R              Both     74       I-IV     None       RT-qPCR      108                 OS^u^    0.14                  0.04-0.49

  335       Yang B, 2016 \[[@R41]\]                 China                     R              Tissue   50       I-IV     Median     qRT-PCR      60                  OS^u^    4.88                  1.90-12.55

  335       Zhang JK, 2017 \[[@R128]\]              China                     R              Frozen   221      I-IV     Median     qRT-PCR      60                  DFS^u^   1.65                  1.11-2.45

  451       Ren C, 2016 \[[@R4]\]                   China                     R              FFPE     180      I-IV     None       ISH          97.2                OS^m^    2.01                  1.36-2.96

  451       Bandres E, 2009 \[[@R141]\]             Spain                     R              FFPE     45       I-III    Median     qRT-PCR      172                 OS^u^\   2.023.70              0.76-5.381.57-8.70
                                                                                                                                                                    DFS^m^                         

  451       Brenner B, 2011 \[[@R142]\]             Israel                    R              FFPE     45       I-III    Median     qRT-PCR      50                  RFS^u^   0.05                  0.01-0.29

  451       Su Z, 2015 \[[@R143]\]                  China                     R              FFPE     107      I-IV     Mean       qRT-PCR      72                  OS^u^    1.08                  0.53-2.19

  486-5p    Li CY, 2017 \[[@R56]\]                  TCGA                      R              Tissue   361      I-IV     None       Downloaded   60                  OS^u^    1.85                  1.22-2.81

  486-5p    Chen H, 2015 \[[@R147]\]                China                     R              FFPE     84       I-IV     None       ISH          75                  OS^m^    3.61                  1.99-6.54

  486-5p    Ren C, 2016 \[[@R148]\]                 China                     R              FFPE     84       I-IV     None       ISH          93.6                OS^m^    2.55                  1.39-4.69

  506       Deng J, 2015 \[[@R154]\]                China                     R              Frozen   63       None     None       qRT-PCR      \>60                OS^u^    3.05                  1.19-7.79

  506       Li Z, 2015 \[[@R155]\]                  China                     R              Frozen   84       I-IV     Mean       qRT-PCR      \>60                OS^u^    1.76                  0.73-4.27

  506       Sakimura S, 2015 \[[@R156]\]            Japan                     R              Tissue   141      I-IV     Median     qRT-PCR      \>140               OS^m^    1.90                  1.05-3.59
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HR (L/H): hazard ratios of low expression versus high expression of miRNAs; HR (H/L): hazard ratios of high expression versus low expression of miRNAs; CI: confidence intervals; TCGA: The Cancer Genome Atlas; R: retrospective; P: prospective; FFPE: formalin-fixed paraffin-embedded; ROC: receiver operating characteristic; qRT-PCR: quantitative real-time polymerase chain reaction; RT-qPCR: reverse transcription quantitative real-time polymerase chain reaction; IHC: immunohistochemistry; ISH: *in-situ* hybridization; OS: overall survival; RFS: recurrence-free survival; CSS: cause-specific survival; DFS: disease-free survival; PFS: progression-free survival; ^u^Univariate analysis; ^m^Multivariate analysis. In order to facilitate read and statistics, studies estimating prognostic value of different miRNAs are shown in blue and white; studies which cannot be merged are shown in yellow.

Meta-analysis {#s2_4}
-------------

A summary of the HR evaluated from the whole combined analysis for all the miRNAs was shown in Table [3](#T3){ref-type="table"}.

###### Summary of the HR for miRNA expression in gastric cancer

  miRNA            Survival analysis   Number of articles   Included references   HR     95%CI        Figure   P value   Heterogeneity (Higgins I2 statistic)   Total patients
  ---------------- ------------------- -------------------- --------------------- ------ ------------ -------- --------- -------------------------------------- ----------------
  High miR-20a     OS                  3                    3,5,11                1.25   0.84-1.87    3        0.27      I2=70.7%, P=0.03                       199
  High miR-20b     OS                  3                    3,12,13               2.38   1.16-4.87    3        0.02      I2=0.0%, P=0.60                        178
  High miR-21      RFS/CSS             3                    6,14,17               2.10   0.72-6.12    2A       0.17      I2=65.6%, P=0.06                       180
  High miR-21      OS                  5                    3,15,16,18,19         1.77   1.01-3.08    2A       \<0.05    I2=57.8%, P=0.05                       327
  Low miR-27b      OS                  3                    32-34                 1.18   0.75-1.85    3        0.47      I2=36.1%, P=0.21                       319
  Low miR-34a      OS                  5                    3,38-41               1.25   0.59-2.65    2D       0.56      I2=68.4%, P=0.13                       457
  Low miR-34a      OS^m^               2                    38,40                 1.56   0.95-2.55    2D       0.08      I2=51.0%, P=0.15                       213
  High miR-106b    OS                  2                    3,45                  1.84   1.15-2.94    3        0.01      I2=0.0%, P=0.67                        157
  High miR-107     OS                  3                    3,46,47               1.52   0.42-5.57    3        0.52      I2=88.8%, P\<0.01                      248
  Low miR-125a     OS                  3                    49-51                 2.06   1.26-3.37    4        \<0.01    I2=0.0%, P=0.42                        230
  Low miR-137      OS                  2                    62,64                 3.21   1.68-6.13    4        \<0.01    I2=6.0%, P=0.35                        168
  Low miR-141      OS                  2                    65,67                 2.47   1.34-4.56    4        \<0.01    I2=0.0%, P=0.66                        125
  High miR-143     OS                  2                    3,70                  0.68   0.12-3.81    4        0.66      I2=48.8%, P=0.16                       81
  Low miR-145      OS                  3                    34,56,72              1.62   1.07-2.46    4        0.02      I2=36.9%, P=0.21                       608
  Low miR-146a     OS                  3                    74-76                 2.60   1.63-4.13    5        \<0.01    I2=14.1%, P=0.31                       213
  High miR-150     OS                  3                    12,77,79              1.63   0.77-3.45    5        0.20      I2=47.8%, P=0.15                       223
  High miR-150     RFS/PFS             2                    77,79                 1.96   1.25-3.05    5        \<0.01    I2=0.0%, P=0.79                        158
  Low miR-183      OS                  3                    56,83,84              1.46   0.55-3.83    5        0.45      I2=90.2%, P\<0.01                      478
  High miR-192     OS                  3                    48,79,87              1.71   0.60-4.85    5        0.31      I2=87.0%, P\<0.01                      140
  High miR-196a    OS                  4                    88,90-92              2.66   1.94-3.63    6        \<0.01    I2=0.0%, P=0.62                        286
  High miR-196b    OS                  4                    56,91-93              1.67   1.38-2.02    6        \<0.01    I2=0.0%, P=0.62                        625
  Low miR-200c     OS                  3                    96,98,99              0.65   0.16-2.64    6        0.54      I2=93.6%, P\<0.01                      276
  Low miR-200c     PFS/DFS             3                    66,96,98              1.20   0.60-2.38    6        0.61      I2=83.1%, P\<0.01                      241
  Low miR-206      OS                  3                    104-106               2.85   1.73-4.70    7        \<0.01    I2=0.0%, P=0.37                        468
  High miR-214     OS                  4                    1,34,110,111          1.84   1.27-2.67    7        \<0.01    I2=23.0%, P=0.27                       403
  Low miR-218      OS                  3                    114-116               2.61   1.74-3.92    7        \<0.01    I2=0.0%, P=0.77                        220
  Low miR-335      OS                  2                    41,127                0.85   0.03-27.50   7        0.93      I2=94.9%, P\<0.01                      124
  Low miR-451      OS                  3                    4,141,143             1.73   1.19-2.52    8        \<0.01    I2=14.7%, P=0.31                       332
  Low miR-451      DFS/RFS             2                    141,142               0.46   0.01-31.06   8        0.72      I2=95.0%, P\<0.01                      90
  Low miR-486-5p   OS                  3                    56,147,148            2.45   1.65-3.65    8        \<0.01    I2=40.0%, P=0.19                       529
  Low miR-506      OS                  3                    154-156               2.07   1.33-3.23    8        \<0.01    I2=0.0%, P=0.65                        288

HR: hazard ratios; CI: confidence intervals; OS: overall survival; RFS: recurrence-free survival; CSS: cause-specific survival; PFS: progression-free survival; DFS: disease-free survival; ^m^Multivariate analysis.

High expression of miR-21 predicts poor OS {#s2_5}
------------------------------------------

Five studies \[[@R3], [@R15], [@R16], [@R18], [@R19]\] analyzed associations between high expression of miR-21 and OS, indicating that GC patients with high miR-21 expression had a significantly shorter OS than those with low miR-21 expression (HR=1.77, 95%CI=1.01-3.08, P\<0.05, Figure [2A](#F2){ref-type="fig"}).

![**(A)** Forest plot of the analyses about high expression of miR-21 and RFS/CSS or OS; **(B)** Publication bias of the analysis about high expression of miR-21 and OS; **(C)** Sensitivity analysis of the study about high expression of miR-21 and OS; and **(D)** Forest plot of the analyses about low expression of miR-34a and OS or OS (multivariate analysis).](oncotarget-08-55489-g002){#F2}

No significant association between high expression of miR-21 and RFS/CSS {#s2_6}
------------------------------------------------------------------------

Three researches \[[@R6], [@R14], [@R17]\] focused on connections between high expression of miR-21 and RFS/CSS, suggesting that there was no significant association between high expression of miR-21 and RFS/CSS (HR=2.10, 95%CI=0.72-6.12, P=0.17, Figure [2A](#F2){ref-type="fig"}).

Publication bias {#s2_7}
----------------

In order to evaluate publication bias for OS of GC patients with high miR-21 expression, the Begg\'s funnel plot was used by us (Figure [2B](#F2){ref-type="fig"}). And the P value was 0.62, indicating absence of publication bias.

Sensitivity analysis {#s2_8}
--------------------

During the study about OS of GC patients with high miR-21 expression, our sensitivity analysis did not indicate alterations in the results according to the exclusion of any individual study (Figure [2C](#F2){ref-type="fig"}), suggesting that no single research significantly influenced the pooled HR and the 95%CI.

No significant association between low expression of miR-34a and OS or OS (multivariate analysis) {#s2_9}
-------------------------------------------------------------------------------------------------

There was no significant association between low expression of miR-34a and OS (HR=1.25, 95%CI=0.59-2.65, P=0.56, Figure [2D](#F2){ref-type="fig"}) or OS (multivariate analysis, HR=1.56, 95%CI=0.95-2.55, P=0.08, Figure [2D](#F2){ref-type="fig"}).

GC patients with high expression of miR-20b, 106b, 196a, 196b, 214 or low expression of miR-125a, 137, 141, 145, 146a, 206, 218, 451, 486-5p, 506 have a significantly poor OS {#s2_10}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The details were shown in Table [3](#T3){ref-type="table"} and Figures [3](#F3){ref-type="fig"}-[8](#F8){ref-type="fig"}.

![Forest plot of the analyses about high expression of miR-20a, 20b, 106b, 107 or low expression of miR-27b and OS](oncotarget-08-55489-g003){#F3}

No significant association between high expression of miR-20a, 107, 143, 150, 192 or low expression of miR-27b, 183, 200c, 335 and OS {#s2_11}
-------------------------------------------------------------------------------------------------------------------------------------

The details were shown in Table [3](#T3){ref-type="table"} and Figures [3](#F3){ref-type="fig"}-[7](#F7){ref-type="fig"}.

![Forest plot of the analyses about high expression of miR-143 or low expression of miR-125a, 137, 141, 145 and OS](oncotarget-08-55489-g004){#F4}

![Forest plot of the analyses about high expression of miR-150, 192 or low expression of miR-146a, 183 and OS or RFS/PFS](oncotarget-08-55489-g005){#F5}

![Forest plot of the analyses about high expression of miR-196a, 196b or low expression of miR-200c and OS or PFS/DFS](oncotarget-08-55489-g006){#F6}

![Forest plot of the analyses about high expression of miR-214 or low expression of miR-206, 218, 335 and OS](oncotarget-08-55489-g007){#F7}

DISCUSSION {#s3}
==========

Present situation {#s3_1}
-----------------

Increasing evidence has shown that various miRNAs are associated with survival outcome in GC patients \[[@R1]--[@R167]\]. However, inconsistent results have emerged. For example, expression levels of miR-200c are up-regulated in blood \[[@R98], [@R99]\] but down-regulated \[[@R66], [@R96]\] in tissue compared with normal samples. Furthermore, expression levels of miR-214 \[[@R1], [@R34], [@R110], [@R111]\] and miR-451 \[[@R4], [@R141]--[@R143]\] are unsteadily expressed (up or down). Surprisingly, there are significant associations between aberrant expression levels of them and OS (P\<0.05, Table [3](#T3){ref-type="table"}, Figures [7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"}). Therefore, it is essential to conduct a meta-analysis to better understand associations between expression levels of miRNAs and prognosis of GC patients.

![Forest plot of the analyses about low expression of miR-451, 486-5p, 506 and OS or DFS/RFS](oncotarget-08-55489-g008){#F8}

Main findings {#s3_2}
-------------

We performed the meta-analyses about 26 miRNAs and OS. As the most studied miRNA, GC patients with high miR-21 expression have a significantly poorer OS than those with low miR-21 expression (P\<0.05). But there is no significant association between high miR-21 expression and RFS/CSS (P=0.17). According to our reference standard, miR-21 is still considered to be a significantly prognostic biomarker. There are some other miRNAs with significantly prognostic value in GC, including miR-20b, 106b, 125a, 137, 141, 145, 146a, 196a, 196b, 206, 214, 218, 451, 486-5p and 506 (P\<0.05). Among them, miR-20b, 125a, 137, 141, 146a, 196a, 206, 218, 486-5p and 506 are strong biomarkers of prognosis in GC (HR≥2).

Molecular mechanisms for studied miRNAs {#s3_3}
---------------------------------------

In addition to the findings mentioned above, a summary of miRNAs with altered expression, their potential targets and pathways entered this study is detailed in Table [4](#T4){ref-type="table"}. It is remarkable that there is functional overlapping or connection among those miRNAs. Twenty miRNAs (miR-20a, 27b, 34a, 106b, 107, 125a, 137, 141, 143, 146a, 183, 192, 196a, 196b, 200c, 214, 218, 335, 451 and 506) are involved in cell functions, including cell apoptosis, colony formation, cycle, differentiation and so on. Zhou et al. \[[@R66]\] reported that miR-200c/141 likely increased E-cadherin expression indirectly through down-regulating ZEB1/2, indicating that this pathway may participate in GC migration and invasion. Additionally, Tsai et al. \[[@R91]\] found that GC cell migration and invasion was enhanced by overexpression of miR-196a/-196b and radixin was recognized as a target of miR-196a/-196b. In a word, these relationships may be involved in the progression of GC.

###### Summary of miRNAs with altered expression, their potential targets and pathways entered this study

  miRNA    Reference      Expression                Potential target            Pathway
  -------- -------------- ------------------------- --------------------------- ---------------------------------------------------------------------------------------
  20a      3,5,11         Up                        E2F1, HIPK1                 Cell differentiation, proliferation, self-renewal and Wnt/β-catenin signaling
  20b      3,12,13        Up                        None                        None
  21       3,6,14-19      Up                        None                        None
  27b      32-34          Down                      CCNG1, VEGF-C               Cell migration and proliferation
  34a      3,38-41        Down                      MET, Survivin               Cell apoptosis, colony formation, invasion and proliferation
  106b     3,6,45         Up                        PTEN                        Cell invasion and migration
  107      3,46,47        Up                        DICER1                      Cell invasion and migration
  125a     49-51          Down                      VEGF-A, ERBB2               Cell proliferation
  137      62-64          Down                      KLF12, MYO1C, CDK6          Cell cycle, differentiation, migration and proliferation
  141      65-67          Down                      ZEB1/2, E-cadherin, IGF1R   Cell colony formation, cycle, invasion, migration, viability and TGF-β/ZEB signaling
  143      3,69,70        Down                      BACH1                       Cell invasion, proliferation and TGF-β/Mad signaling
  145      34,56,72,73    Down                      α-SMA                       None
  146a     74-76          Down                      EGFR, IRAK1, LIN52          Cell apoptosis, invasion, migration and proliferation
  150      12,77,79       Up                        None                        None
  183      56,83,84       Down                      EZR, BMI1                   Cell colony formation, invasion and proliferation
  192      48,79,87       Up                        None                        Cell invasion
  196a     88,90-92       Up                        CDKN1B, Rdx                 Cell colony formation, cycle, invasion, migration and proliferation
  196b     56,91-93       Up                        Rdx                         Cell invasion and migration
  200c     98,9966,96     Up (blood)Down (tissue)   ZEB1/2, E-cadherin          Cell invasion, migration and TGF-β/ZEB signaling
  206      104-106        Down                      None                        None
  214      1,34,110,111   Up or Down                CSF1, PTEN                  Cell invasion, migration and proliferation
  218      114-116        Down                      ROBO1                       Cell invasion and sli/ROBO1 signaling
  335      41,127,128     Down                      Survivin, BIRC5, CRKL       Cell apoptosis, cycle, growth, invasion, migration and proliferaion
  451      4,141-143      Up or Down                MIF                         Cell invasion, migration and proliferation
  486-5p   56,147-148     Down                      FGF9                        None
  506      154-156        Down                      Yap1, ETS1, SNAI2           Cell epithelial-mesenchymal transition, growth, invasion, migration and proliferation

E2F1: E2F transcription factor 1; HIPK1: homeodomain interacting protein kinase 1; CCNG1: cyclin G1; VEGF: vascular endothelial growth factor; PTEN: protein tyrosine phosphatase and tensin homologue; DICER1: dicer 1, ribonuclease type III; ERBB2: erb-b2 receptor tyrosine kinase 2; KLF12: krűppel-likefactor 12; MYO1C: myosin 1C; ZEB1/2: zinc finger E-boxbinding homeobox 1/2; IGF1R: insulin-like growth factor 1 receptor; BACH1: BTB domain and CNC homolog 1; α-SMA: α smooth muscle actin; EGFR: epidermal growth factor receptor; IRAK1: interleukin 1 receptor associated kinase 1; LIN52: lin-52 homolog (C. elegans); EZR: ezrin; BMI1: BMI1 proto-oncogene, polycomb ring finger; CDKN1B: cyclin dependent kinase inhibitor 1B; Rdx: radixin; CSF1: colony stimulating factor 1; Robo1: roundabout guidance receptor 1; BIRC5: baculoviral IAP repeat containing 5; CRKL: CRK like proto-ongogene, adaptor protein; MIF: macrophage migration inhibitory factor (glycosylation-inhibiting factor); FGF9: fibroblast growth factor 9; YAP1: Yes associated protein 1; ETS1: ETS proto-oncogene 1, transcription factor; SNAI2: snail family transcriptional repressor 2; TGF-β: transforming growth factor-β; Mad: mothers against dpp; AKT1: AKT serine/threonine kinase 1; sli: slit.

Strengths of the meta-analysis {#s3_4}
------------------------------

This meta-analysis has several strengths which are as follows: (1) we searched almost all articles with survival outcomes in GC patients with diverse miRNAs. Moreover, the present expression profile of miRNAs was clearly listed in Table [1](#T1){ref-type="table"} in terms of names of miRNAs; (2) articles measuring at least one of survival curves about OS, CSS, DFS, RFS, PFS and MFS were finally included and articles only reporting HR or 95%CI without any of survival curves were excluded by us; (3) miRNAs investigated more than or equal to 3 times were conducted meta-analyses; (4) almost all sample sizes of included studies are more than or equal to 30 (except 1 study \[[@R64]\]), enhancing the power and broadening the applicability of the outcomes to GC patients.

Limitations {#s3_5}
-----------

However, one should keep in mind the following limitations: (1) 1 miRNA considered as significant biomarker of prognosis contained a high heterogeneity (miR-21); (2) there are many variables among the present meta-analysis, such as different types of samples (tissue, plasma and serum), disease stages, cut-off values and miRNA methods; (3) our meta-analysis only included English articles, which might exclude certain relevant articles with other languages; (4) articles only reporting HR or 95%CI without survival curves were excluded by us, reducing the sample sizes of included articles; (5) as a result of substantial relevant articles and data about GC, we subjectively and selectively included some researches according to the criteria of inclusion and exclusion (Table [5](#T5){ref-type="table"}), leading to ignore a few potential miRNAs with prognostic value.

###### Information of search methods and criteria of inclusion and exclusion

  Methods              Information
  -------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Search strategy      4 search engines, including PubMed, EMBASE, Web ofScience and Cochrane Database of Systematic Reviews
  Search deadline      March 19, 2017
  Search term          mir and gastric cancer
  Inclusion criteria   \(1\) Patients with gastric cancer;(2) Expression of miRNAs and survival outcome intissue, plasma or serum were measured;(3) At least, one of survival curves about overall survival(OS), cause-specific survival (CSS), disease-free survival(DFS), recurrence-free survival (RFS), progression-freesurvival (PFS) and metastasis-free survival (MFS)was measured, with or without the HR or 95%CI;(4) Full text articles in English
  Exclusion criteria   \(1\) Reviews, letters or laboratory studies withoutoriginal data and retracted articles;(2) Frequency of studies estimating prognostic valueof miRNAs ≤2;(3) Studies which cannot be merged;(4) If more than one article had been published on theidentical study cohort, only the most comprehensivestudy was selected for the present meta-analysis

Implications for future clinical and scientific research {#s3_6}
--------------------------------------------------------

It is worth mentioning that this meta-analysis is the first systematic estimation of the relevance between miRNA expression and prognosis of GC patients. There are some implications for future clinical and scientific research in the present meta-analysis: (1) for clinical doctors and other healthcare providers, combined detection of miRNA expression can greatly enhance the estimation about survival time of GC patients and timely treatment can be offered; (2) for scientific researchers, the present study trend on associations between miRNAs and prognosis of GC patients can be conveniently seen in Table [1](#T1){ref-type="table"}. As a result, selectively basic experiments can be performed by them (Table [4](#T4){ref-type="table"}); (3) inconsistent outcomes of prognosis about miRNAs may be solved according to the basement of the current meta-analysis.

MATERIALS AND METHODS {#s4}
=====================

Search strategy, inclusion criteria and exclusion criteria {#s4_1}
----------------------------------------------------------

The details were presented in Table [5](#T5){ref-type="table"}. Two authors (Yue Zhang and Dong-Hui Guan) independently performed this comprehensive online search.

Quality assessment {#s4_2}
------------------

Yue Zhang and Dong-Hui Guan confirmed all eligible investigations that analyzed the prognostic value of miRNAs in GC, and Yue-Hua Jiang reassessed uncertain data.

Statistical analysis {#s4_3}
--------------------

All analyses were conducted using Stata version 13.0 (StataCorp, College Station, Texas, USA). The relative effect sizes for HR were characterized as moderate (protective \[0.51-0.75\] or contributory \[1.35-1.99\]) and large (≤0.50 or≥2). The HR was considered significant at the P\<0.05 level if the 95%CI did not include the value 1. If the P values from OS and other survival results about corresponding miRNAs were inconsistent, the HR from OS was considered to the main reference standard. Because different types of samples (tissue, plasma and serum) from GC patients at different disease stages, cut-off values and miRNA methods were used in individual studies, random-effects models (DerSimonian-Laird method) were more appropriate than fixed-models (Mantel-Haenszel method) for most of the analyses. Consequently, the random-effects models were used in the current meta-analysis. Publication bias was estimated using the Begg\'s funnel plot. A two-tailed P value \<0.05 was considered significant. Sensitivity analysis (influence analysis) was carried out to test how powerful the combined effect size was to removal of individual investigations. If the point assessment was out the 95%CI of the pooled effect size after it was removed from the analysis, an individual study was doubted to have excessive influence.

CONCLUSIONS {#s5}
===========

In summary, miR-20b, 21, 106b, 125a, 137, 141, 145, 146a, 196a, 196b, 206, 214, 218, 451, 486-5p and 506 demonstrate significantly prognostic value. Among them, miR-20b, 125a, 137, 141, 146a, 196a, 206, 218, 486-5p and 506 are strong biomarkers of prognosis in GC.
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